AMD
Advanced Micro Devices, Inc.
AMD has the edge over DBD overall, supported by stronger fundamentals and stronger modeled upside.
DBD
Diebold Nixdorf, Incorporated
DBD has slightly lower modeled downside risk, despite its lower overall score.
AMD Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
AMD's revenue, profitability, cash flow and balance sheet are all currently strong.
DBD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Stable |
DBD's profitability is currently healthy, and its revenue, cash flow and balance sheet are stable.
AMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 39x | $585 | — |
| Cheap | 40x | $182 | -69% |
| Fair | 112x | $514 | -12% |
| Current | 127x | $585 | — |
| Expensive | 206x | $947 | +62% |
Historical ranges are pointers, not guarantees.
AMD has the edge over DBD in the historical PE scenario, which offers more potential upside but is not a forecast.
DBD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 0.7x | $1.54 | -97% |
| Forward | 9.8x | $54.75 | — |
| Fair | 22x | $44.94 | -18% |
| Current | 26x | $54.75 | — |
| Expensive | 32x | $67.83 | +24% |
Historical ranges are pointers, not guarantees.
DBD's PE is in its fair range at 26x. If earnings grow as analysts expect, today's price would be 9.8x next year's earnings.
AMD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Broad | |
| Low |
AMD has the edge over DBD on the outlook, with more favorable revenue expectations.
DBD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect DBD's earnings to grow and its profitability to improve, with its revenue holding steady.
AMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $15.05 | +227% |
| Q3 2026 | $4.60 | +127% |
| Q2 2026 | $3.89 | +122% |
| Q1 2026 | $3.05 | +123% |
| Q4 2025 | $2.65 | +165% |
| Q3 2025 | $2.03 | +81% |
| Q2 2025 | $1.75 | +111% |
| Q1 2025 | $1.37 | +99% |
| Q4 2024 | $1.00 | +89% |
AMD has the edge over DBD on earnings, with more consistent year-over-year improvement.
DBD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.56 | +166% |
| Q3 2026 | $2.09 | +53% |
| Q2 2026 | $3.01 | +$3.35 |
| Q1 2026 | $2.90 | +$3.17 |
| Q4 2025 | $2.54 | +$2.98 |
| Q3 2025 | $1.37 | +$1.37 |
| Q2 2025 | -$0.34 | -101% |
| Q1 2025 | -$0.27 | -101% |
| Q4 2024 | -$0.44 | -101% |
DBD's earnings per share have fallen from their peak: $2.09 over the past year, against $57.03 in mid-2024.
AMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13.4B | +45% |
| Q2 2026 | $11.5B | +50% |
| Q1 2026 | $10.3B | +38% |
| Q4 2025 | $10.3B | +34% |
| Q3 2025 | $9.2B | +36% |
| Q2 2025 | $7.7B | +32% |
| Q1 2025 | $7.4B | +36% |
| Q4 2024 | $7.7B | +24% |
AMD has the edge over DBD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +7.4 points |
| Q2 2026 | 17% | +19 points |
| Q1 2026 | 14% | +3.6 points |
| Q4 2025 | 17% | +5.7 points |
| Q3 2025 | 14% | +3.1 points |
| Q2 2025 | -1.7% | -6.4 points |
| Q1 2025 | 11% | +10 points |
| Q4 2024 | 11% | +5.8 points |
AMD has the edge over DBD on profitability, with a higher operating margin.
DBD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $994.3M | +5.2% |
| Q2 2026 | $930.8M | +1.7% |
| Q1 2026 | $891.8M | +6% |
| Q4 2025 | $1.1B | +12% |
| Q3 2025 | $945.2M | +2% |
| Q2 2025 | $915.2M | -2.6% |
| Q1 2025 | $841.1M | -6.1% |
| Q4 2024 | $988.9M | -4.6% |
DBD's revenue has grown year over year for five quarters in a row: $994M last quarter, up 5.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.9% | -3.9 points |
| Q2 2026 | 6.2% | 0 points |
| Q1 2026 | 3.7% | +0.1 points |
| Q4 2025 | 7.5% | +3.3 points |
| Q3 2025 | 7.8% | +2.8 points |
| Q2 2025 | 6.1% | -1.4 points |
| Q1 2025 | 3.5% | +0.9 points |
| Q4 2024 | 4.2% | -1.2 points |
DBD's operating margin was 3.9% last quarter, down 3.9 points from the same quarter a year ago.
AMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $554M | -71% |
| Q2 2026 | $1.6B | -9.9% |
| Q1 2026 | $2.6B | +253% |
| Q4 2025 | $2.4B | +118% |
| Q3 2025 | $1.9B | +283% |
| Q2 2025 | $1.7B | +294% |
| Q1 2025 | $727M | +92% |
| Q4 2024 | $1.1B | +351% |
AMD generated $7.1B in free cash flow over the past year, up 30% from the year before.
DBD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$47.4M | -227% |
| Q2 2026 | -$13.6M | -145% |
| Q1 2026 | $31.7M | +102% |
| Q4 2025 | $217.5M | +11% |
| Q3 2025 | $37.4M | +$52.9M |
| Q2 2025 | $30.1M | +$38.1M |
| Q1 2025 | $15.7M | +$39.2M |
| Q4 2024 | $196.2M | +26% |
DBD has burned cash in most quarters: $188M over the past year, down 33% from the year before.
AMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +2M shares |
| 1 year | +1.2% | +20M shares |
| 3 years | +2% | +32M shares |
| 5 years | +35% | +431M shares |
| Available history | +40% | +473M shares |
AMD has 1.7B diluted shares, up 1.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $221M |
| Q4 2025 | — |
| Q3 2025 | $89M |
| Q2 2025 | $478M |
| Q1 2025 | $749M |
| Q4 2024 | $256M |
AMD has spent almost nothing on buybacks in the past year.
DBD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -700K shares |
| 1 year | -6.5% | -2.4M shares |
| 3 years | -7.9% | -3M shares |
| 5 years | -56% | -43.7M shares |
| Available history | -55% | -42.2M shares |
DBD has the edge over AMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $33.9M |
| Q2 2026 | $60.6M |
| Q1 2026 | $60.4M |
| Q4 2025 | $51.1M |
| Q3 2025 | $39.9M |
| Q2 2025 | $30.1M |
| Q1 2025 | $9.6M |
| Q4 2024 | $2.3M |
DBD spent $206M buying back its own shares over the past year, up 152% from the year before.
AMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2020 | -1.0x | Net Cash |
| Q1 2020 | -0.8x | Net Cash |
| Q4 2019 | -1.2x | Net Cash |
AMD has more cash than debt.
DBD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.3x | Moderate |
| Q2 2026 | 1.8x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 2.2x | Moderate |
| Q2 2025 | 2.5x | Moderate |
| Q1 2025 | 2.7x | Moderate |
| Q4 2024 | 2.8x | Moderate |
DBD's net debt is about 2.3 years of its operating earnings (EBITDA), about the same as a year ago.
AMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.3 | Neutral |
| Stochastic | 41.4 | Neutral |
AMD's weekly RSI is 59 (neutral) and its Stochastic is 41 (neutral).
DBD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.8 | Neutral |
| Stochastic | 11.4 | Oversold |
DBD's weekly RSI is 35 (neutral) and its Stochastic is 11 (oversold).
AMD PE vs Technology Sector
| Metric | AMD | Sector median | Relative |
|---|---|---|---|
| PE | 127x | 28x | 357% above |
| PE % | 61 | 35 | 26 pts above |
AMD is trading at 127x earnings, a 357% premium to the Technology sector's median of 28x.
DBD PE vs Technology Sector
| Metric | DBD | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 28x | 6% below |
| PE % | 61 | 25 | 36 pts above |
DBD has the edge over AMD on valuation relative to its sector.
AMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $557.2 | 5.1% above |
| 20 week MA | $525.9 | 11% above |
| 50 week MA | $389.7 | 50% above |
| 100 week MA | $266.9 | 119% above |
| 200 week MA | $199.6 | 193% above |
AMD has stronger trend alignment. AMD is above 5 of 5 weekly averages versus DBD above 0 of 4.
DBD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.8 | 11% below |
| 20 week MA | $69.7 | 21% below |
| 50 week MA | $73.3 | 25% below |
| 100 week MA | $62.4 | 12% below |
DBD is in a downtrend: it's below all four of its weekly moving averages, and 12% below its 100-week average.
AMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $46.2 | $91.8 | +99% |
| 2021 | $91.8 | $146.1 | +59% |
| 2022 | $146.1 | $64.5 | -56% |
| 2023 | $64.5 | $147.4 | +128% |
| 2024 | $147.4 | $125.2 | -15% |
| 2025 | $125.2 | $215.0 | +72% |
| 2026 YTD | $215.0 | $585.3 | +172% |
AMD has the edge over DBD on returns for 2026, with the stronger performance.
DBD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $20.1 | $29.0 | +44% |
| 2024 | $29.0 | $42.9 | +48% |
| 2025 | $42.9 | $69.3 | +61% |
| 2026 YTD | $69.3 | $54.8 | -21% |
DBD has finished every year since 2023 higher, and it's down 21% so far in 2026.